Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study
Clinical and Translational Science · 2026-03 · 19 (3)
DOI: 10.1111/cts.70526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 13.03.2026. Verfasst von Leila Potzel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Benzoxazines, Coproporphyrins, Hemeproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Coproporphyrin I (CPI) is increasingly recognized as a reliable endogenous biomarker for hepatic OATP1B transporters. However, confounding mechanisms such as increased heme biosynthesis driven by induction of CYP enzymes, which are hemoproteins, may affect CPI levels independently of OATP1B1 inhibition. The aim of this study was to investigate whether activation of nuclear receptors and subsequent CYP induction by efavirenz affects CPI levels in vitro and in vivo. We first evaluated the potential of efavirenz to interact with OATP1B1 in vitro. We then assessed efavirenz‐induced changes in vitro, analyzing the mRNA expression of CYP2B6 and both mRNA and protein expression of ALAS1 (5‐aminolevulinate synthase 1), the rate‐limiting enzyme in heme biosynthesis. Additionally, we quantified CPI levels in the cell culture supernatant. Finally, we determined plasma CPI levels in healthy volunteers pre‐ and post‐induction with efavirenz. In transport studies, efavirenz did not alter OATP1B1‐mediated uptake of CPI, whereas rosuvastatin reduced their intracellular accumulation. Treatment with efavirenz significantly increased CYP2B6 mRNA expression, confirming CYP induction in vitro, but had no effect on ALAS1 expression at either mRNA or protein level. Correspondingly, CPI levels in the cell supernatant remained unchanged after efavirenz treatment compared to solvent control. In vivo, plasma CPI levels were also unaffected by efavirenz. Our in vitro findings demonstrate that while efavirenz induces CYP expression, it does not impact ALAS1 expression or alter CPI levels, supported by our in vivo findings where efavirenz did not change plasma CPI, suggesting that CYP enzyme induction does not relevantly affect coproporphyrin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
- Center of Drug Absorption and Transport, Institute for Pharmacology, University Medicine Greifswald, Greifswald, Germany.
ORCID-Profile: Leila Potzel, Jonny Kinzi, Markus Grube, Werner Siegmund, Henriette E Meyer Zu Schwabedissen
Zitieren
APA
Potzel, L., Kinzi, J., Seibert, I., Grube, M., Siegmund, W., & Meyer Zu Schwabedissen, H. E. (2026). Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study. Clinical and Translational Science, 19(3). https://doi.org/10.1111/cts.70526
Vancouver
Potzel L, Kinzi J, Seibert I, Grube M, Siegmund W, Meyer Zu Schwabedissen HE. Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study. Clinical and Translational Science. 2026;19(3). doi:10.1111/cts.70526
BibTeX
@article{Potzel2026,
author = {Potzel, Leila and Kinzi, Jonny and Seibert, Isabell and Grube, Markus and Siegmund, Werner and Meyer Zu Schwabedissen, Henriette E},
title = {Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {3},
doi = {10.1111/cts.70526}
}
EUVIMED